Muira Puama: A Name On Every Vitality Label, A Trial That Has Never Been Run In Humans

Sourced from the product label and PubMed-indexed researchLast updated September 202612 min readIngredient evidence

Most of the other eight names on the Jelly Force panel have at least one study with a human component behind the claim they are sold on — a randomised trial in men, a pharmacokinetic study in volunteers, or at minimum a laboratory assay run on a human enzyme — even where the amount used was far larger than this blend carries. Muira puama’s modern published research has none of that. It is the first name printed on the panel’s ingredient line, it appears on most labels in this category, and every study behind it that this article could locate on PubMed is preclinical: mice, and plant chemistry. No human trial, for sexual function, libido, vitality or anything else, has ever been published on it. This article sets out what has actually been studied, and what a name that old and that common is standing in for.

What muira puama actually is

Muira puama is the common name for Ptychopetalum olacoides, a small tree native to the Brazilian Amazon whose bark and root have a long history of use in the region as a general tonic, taken for fatigue, nervous exhaustion and, among other traditional indications, as an aphrodisiac. The name itself is sometimes translated loosely as “potency wood.” It has been sold in Western herbal commerce since at least the late nineteenth century, most often as a component of multi-ingredient tonics rather than as a single-ingredient product, which is exactly the role it plays on this label: one of nine names inside an 82 mg blend, with no amount printed for muira puama specifically.

That history matters for how to read what follows. A plant used in a region for well over a century, across a range of traditional indications, is not the same claim as a plant with a modern clinical trial behind the specific use it is marketed for today. Both kinds of evidence exist in herbal medicine, and this website treats them differently on every ingredient page: traditional use as a reason a plant was investigated, and published trial data as the answer to whether the investigation supported the traditional claim. For muira puama, on the specific claim this bottle is sold on, that second step has not happened.

What the Jelly Force panel says, and what the advertising claims

The Supplement Facts panel lists “Muira Puama Extract” first among the nine names inside the 82 mg proprietary blend, with no standalone amount, no extract ratio and no marker compound — the same gap this website’s standardization article covers for the panel as a whole. The vendor’s own advertising tile, headed INSIDE JELLYFORCE, names muira puama among the five ingredients it singles out, generally framed alongside catuaba and maca as part of the formula’s traditional-tonic identity.

Nothing about that framing is inaccurate as a description of tradition. Muira puama genuinely has that reputation, genuinely appears across this product category under that reputation, and genuinely is the kind of name a buyer skimming an ingredient list would recognise as belonging to the “natural vitality” shelf. The question this article asks is narrower: what does the published, PubMed-indexed research on Ptychopetalum olacoides actually contain, once tradition and marketing copy are set aside.

The gap between the marketed use and the published research

A search of the modern pharmacological literature on Ptychopetalum olacoides turns up a small, consistent set of papers, and almost none of them concern sexual function. The closest thing to a human-relevant behavioural study is a rodent stress model, described below. The rest of the modern research divides into two other lines entirely: cognition and neuroprotection in mouse models of memory loss, and the plant chemistry itself — which compounds are actually present in the bark. Neither line was designed to test, and neither reports, anything about libido, erectile response or the vitality claim this bottle is sold under.

That is a materially different situation from most of the other eight names on this panel. Maca, tribulus and L-arginine each have randomised, placebo-controlled human trials, of varying quality, testing something close to the marketed claim, even if the amounts used were far larger than this blend carries. Ashwagandha has the same, plus two published liver case series this website has covered separately. Muira puama has traditional use, a mouse stress study, and a chemistry literature. It does not have a human trial for the claim on the front of this bottle.

The closest thing to a relevant study: mice, chronic stress, and a light/dark test

The single paper on Ptychopetalum olacoides this website has cited before is a 2010 study on its anti-stress effects, and it is worth describing precisely rather than summarising in one line. Researchers gave mice an extract of the bark and put them through an unpredictable chronic mild stress paradigm — a standard rodent model for sustained, low-grade stress — then measured anxiety using a light/dark test, tracking how long each mouse spent in the lit side of its enclosure, alongside blood glucose and the time it took a low-oxygen environment to trigger a convulsion. The extract did not reduce anxiety in unstressed mice, but it did prevent the anxiety-like drop in time spent in the light that chronic stress otherwise caused, prevented the stress-induced rise in blood glucose, and lengthened the time to hypoxia-induced convulsion at several doses (Piato 2010). The authors describe the pattern as consistent with an adaptogen-like effect, on top of antioxidant and neuroprotective properties reported elsewhere.

Two things about that study are worth being explicit about. First, it is an animal study, in mice, and animal behavioural models of chronic stress do not translate directly to a human vitality or libido claim; they translate, at best, to a hypothesis worth testing in humans, which as of this writing has not been done for this plant. Second, even inside its own animal model, the study is about a stress paradigm, blood glucose and convulsion latency, not about sexual response, mounting behaviour or any measure a reader would recognise as related to the claim on this bottle. A “tonic” that blunts a chronic-stress response in a mouse is a genuinely interesting starting point for research. It is not evidence that a gummy improves vitality or drive in a man.

Two more mouse studies, and neither is about libido

The largest body of modern pharmacological work on this plant is not about stress either. It is about cognition, run by a research group that has published on Ptychopetalum olacoides as a candidate treatment for memory loss and neurodegeneration, under its Brazilian folk name Marapuama, described in their own papers as a “brain tonic” used by the elderly in Amazon communities.

One study gave mice a standardized ethanol extract of the bark and measured its effect on an enzyme called acetylcholinesterase in brain regions relevant to memory, the same enzyme class targeted by prescription Alzheimer’s medications; the extract meaningfully inhibited the enzyme in the hippocampus and other memory-relevant areas, consistent with the memory-supporting effects the same research group had observed behaviourally (Figueiró 2010). A follow-up study went further, using a mouse model of Alzheimer’s disease built by injecting a toxic protein fragment directly into the brain, and found that two weeks of oral treatment with the same extract reduced the resulting cognitive impairment and reduced markers of brain cell damage compared to untreated mice (Figueiró 2011).

Both papers describe this as a promising, early-stage neuroprotection finding worth following up clinically, and it is a genuinely interesting research direction on its own terms. It is also, again, a completely different claim from vitality or sexual drive. A reader who sees “muira puama” on this label and assumes the research behind it concerns libido would be pointed, if they looked the ingredient up themselves, toward a set of mouse papers about memory and brain protection instead. That mismatch between what a name is marketed for and what its modern research literature actually studies is the central finding of this article.

What is actually in the bark

Even the basic chemistry of muira puama is a newer, still-developing picture than the plant’s long folk history might suggest. A 2018 phytochemical analysis isolated and identified fourteen compounds from Ptychopetalum olacoides bark, six of them reported in the plant for the first time, and found that two alkaloids, magnoflorine and menisperine, together accounted for roughly seventy-six per cent of everything measured, making them the dominant constituents by far; the phenolic compounds present, by contrast, were found in far smaller amounts (Tian 2018).

The paper’s own framing is worth repeating: this kind of quantitative chemistry is described as necessary groundwork for quality control of muira puama products, precisely because it had not been well established before. That is a plant whose active-compound profile is still being mapped, in 2018, for a product category that has been selling it as an ingredient for well over a hundred years. It underlines the same point the standardization article makes about the rest of this panel: “Muira Puama Extract” without a stated marker compound is not unusual for this plant specifically, because the compound most researchers would use as a marker has only recently been identified with any confidence.

What a 2020 safety review found, and did not find

A 2020 pharmacology review set out specifically to collect the published psychiatric and neurological adverse-effect data on fifteen herbal sexual enhancers, muira puama included, reasoning that any substance capable of shifting sexual desire is also acting on pathways involved in mood and neurological function, and adverse effects are therefore a reasonable thing to expect and look for (Brunetti 2020). Its overall finding across the fifteen plants was that most appeared safe at traditional, therapeutic-range doses, but that mild to severe adverse effects could occur with overdosing or with unstandardized, self-medicated products, and that drug interactions were the bigger concern of the two, since herbal aphrodisiacs are often taken alongside other plant extracts or prescription medicines rather than alone.

What the review could not do, for muira puama specifically, is report a body of clinical safety data the way it could for better-studied plants on its list. It states plainly that for several of the fifteen plants it covers, the underlying published data remain thin, and calls for more controlled clinical studies to close that gap. Combined with the absence of any human efficacy trial described above, muira puama sits in an unusual position on this label: not flagged as dangerous, but also not established as safe or effective by controlled human data at any dose, for the claim it is sold on.

What that leaves a buyer with

Set the whole picture beside the other eight names on this panel and the shape of the gap is clear. This is not a plant with a negative trial behind it, the way tribulus has one negative result alongside a positive one. It is not a plant with a documented organ-specific safety signal, the way this website has covered separately for ashwagandha. It is a plant with a centuries-long traditional reputation for the exact claim it is marketed on here, a modest and unrelated animal literature on stress, a separate and more developed animal literature on cognition that has nothing to do with libido, a chemistry profile still being actively mapped, and a 2020 safety review that could not find enough clinical data to say much more than “probably fine at traditional doses, more research needed.”

None of that makes muira puama an unusual or suspicious ingredient by the standards of this category; several names across this whole shelf share a similar gap between tradition and controlled human trial. What it does mean is that a reader who wants trial evidence specifically for the vitality claim printed on this label, for this one ingredient, will not find it by searching PubMed, no matter how the amount question from the standardization article eventually gets answered. The honest position, and the one this website takes across every ingredient page, is to say so plainly rather than to imply a trial exists where none does.